Insights

Health and Life Sciences icon

Are investor assumptions around NHS insourcing set to be challenged?

Health and Life Sciences

Mark Loughridge
|

Structural and operational pressures – which have long been drivers for growth in the insourcing market – are here to stay, and any easing of these will occur from a high base. However, political scrutiny and pressure is growing and, in the context of the recent NHS Long Term Workforce Plan and a potential Labour government, this raises the risk of greater regulatory…

Read more
Health and Life Sciences icon

Global developments and the future of UK cancer screening

Health and Life Sciences

Mark Loughridge
|

For patients given a timely cancer diagnosis, survival rates have never been better and, with revolutions in genomics and Artificial Intelligence (AI) gathering pace, the tide could soon turn comprehensively in favour of patients. However, the key to ensuring patients can benefit from this innovation is providing a comprehensive and accessible national screening service,…

Read more
Health and Life Sciences icon

Could payment system reform stifle NHS innovation and integration?

Health and Life Sciences

Mark Loughridge
|

Amid a record-breaking elective backlog in England, NHS England has opted to flex its newly-granted financial powers by proposing a partial return to the Payment by Results system for acute care. But does this seemingly technical rewiring of the NHS’s financial flow have actual political and business salience? The answer is yes, and here is why. 

Read more
Health and Life Sciences icon

How exposed is the global health system to geopolitical tensions?

Health and Life Sciences

Mark Loughridge
|

The COVID-19 pandemic has shone a light on the fragility of the public health systems that we take for granted. As the virulence of the pandemic begins to abate across much of the world, how exposed – or prepared – are counties for the impact of war, economic sanctions, political isolation and new migratory patterns on existing health structures and systems? 

Read more
Health and Life Sciences icon

Does the UK government ‘get’ science?

Health and Life Sciences

Mark Loughridge
|

Mark Loughridge, Dr Rupert Lewis, Andrew Croydon and Miranda Lutz discuss the ‘science gap’ between government and scientists.

Read more
Health and Life Sciences icon

Will capacity constraints scupper the UK Government’s vision for post Brexit medical devices regulation?

Health and Life Sciences

Mark Loughridge
|

In September, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued its long-anticipated consultation on the UK’s post Brexit medical devices regime. For all the early talk of substantial divergence from existing EU rules, the UK Government is in fact proposing greater regulatory alignment and a focus on pathways so far not offered by other major…

Read more